Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: A proposal for quantitative immune-related pathologic response criteria (irPRC) Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Lung Neoplasms
  • Quinazolines
  • Receptor, Epidermal Growth Factor

abstract

  • irPRC may be used to standardize pathologic assessment of immunotherapeutic efficacy. Long-term follow-up is needed to determine irPRC reliability as a surrogate for recurrence-free and overall survival.

publication date

  • January 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC6096736

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdy218

PubMed ID

  • 29982279

Additional Document Info

start page

  • 1853

end page

  • 1860

volume

  • 29

number

  • 8